Absence of the K303R estrogen receptor α mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment

Experimental and Therapeutic Medicine

Volumn 1, Issue 6, 2010, Pages 939-942

  Ghimenti, Chiara ^a   Mello Grand, Maurizia ^a   Regolo, Lea ^b   Zambelli, Alberto ^b   Chiorino, Giovanna ^a  

^a Laboratory of Cancer Genomics   (Italy)

^b IRCCS   (Italy)

Author keywords

Aromatase inhibitors; Breast cancer; Estrogen receptor mutation

Indexed keywords

ANASTROZOLE; ANDROSTENEDIONE; ESTROGEN RECEPTOR ALPHA; MUTANT PROTEIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; MUTATION; POSTMENOPAUSE;

EID: 78049283806     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.151     Document Type: Article

References (23)

1. Chalbos D, Vignon F, Keydar Iand Rochefort H: Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J Clin Endocrinol Metab 55: 276-283, 1982.
2. Russo J and Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102: 89-96, 2006.
3. Beatson G: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 147: 101-107, 1986.
4. Smith IE and Dowsett M: Aromatase inhibitors in breast cancer. NEngl J Med 348: 2431-2442, 2003.
5. Osborne CK: Tamoxifen in the treatment of breast cancer. NEngl J Med 339: 1609-1618, 1998.
6. Allred DC, Mohsin SK and Fuqua SA: Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8: 47-61, 2001.
7. Elledge RMand Fuqua SAW: Estrogen and progesterone receptors. In: Diseases of the Breast. Harris JR, Lippman ME, Morrow M, et al (eds). Lippincott, Williams & Wilkins, Philadelphia, pp471-488, 2000.
8. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK and Fuqua SA: Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10: 7490-7499, 2004.
9. Pike MC, Spicer DV, Dahmoush Land Press MF: Estrogens, progestins, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15: 17-35, 1993.
10. McGuire WL, Chamness GC and Fuqua SA: Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5: 1571-1577, 1991.
11. Herynk MH, Parra I, Cui Y, Beyer A, Wu MF, Hilsenbeck SG and Fuqua SA: Association between the estrogen receptor α A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res 13: 3235-3243, 2007.
12. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P and Allred DC: Ahypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res 60: 4026-4029, 2000.
13. Tebbit CL, Bentley RC, Olson JAJr and Marks JR: Estrogen receptor α (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. Genes Chromosomes Cancer 40: 51-54, 2004.
14. Tokunaga E, Kimura Y and Maehara Y: No hypersensitive estrogen receptor-α mutation (K303R) in Japanese breast carcinomas. Breast Cancer Res Treat 84: 289-292, 2004.
15. Davies MP, O'Neill PA, Innes Hand Sibson DR: Hypersensitive K303Roestrogen receptor-α variant not found in invasive carcinomas. Breast Cancer Res 7: R113-R118, 2005.
16. Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Haruki N, Kobayashi S and Iwase H: Estrogen receptor α mutation (A-to-G transition at nucleotide 908) is not found in different types of breast lesions from Japanese women. Breast Cancer 10: 70-73, 2003.
17. Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B and Millikan RC: The estrogen receptor-α A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res 7: R871-R880, 2005.
18. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WVand Fuqua SA: Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity. Cancer Res 64: 9199-9208, 2004.
19. Giordano C, Cui Y, Barone I, Ando S, Mancini MA, Berno Vand Fuqua SA: Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat 119: 71-85, 2010.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
21. Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Andò S and Fuqua SA: Expression of the K303Restrogen receptor-α breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 69: 4724-4732, 2009.
22. Conway K, Parrish E, Edmiston SN, Tolbert Dand Tse CK: Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation. Breast Cancer Res 9: R36, 2007.
23. Li CI, Malone KE, Porter PL, Weiss NS and Tang MT: Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65-79 years of age. Int J Cancer 107: 647-651, 2003.